Bailard’s Xeris Biopharma Holdings XERS Stock Holding History

Bailard’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,300	Closed	-$120K	–	848
2025 Q4	$120K	Buy	+15,300	New	+$120K	﹤0.01%	733
2022 Q4	–	Sell	-56,000	Closed	-$87K	–	792
2022 Q3	$87K	Buy	+56,000	New	+$92.6K	﹤0.01%	635

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bailard's XERS Position: Q1 2026 in Review

Bailard sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 15,300 shares — an estimated $120K sold.

Bailard first reported a position in XERS in Q3 2022 and held it in 2 quarters. The position peaked at $120K in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Bailard reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
Bailard sold 15,300 Xeris Biopharma Holdings shares in Q1 2026, an estimated $120K.
Bailard first reported a position in Xeris Biopharma Holdings in Q3 2022 and held it in 2 quarters.
Bailard's Xeris Biopharma Holdings position peaked at $120K in Q4 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.